Estradiol/levonorgestrel

Estradiol/levonorgestrel
Combination of
Estradiol	Estrogen
Levonorgestrel	Progestogen
Clinical data
Trade names	Climara Pro
Other names	E2/LNG
ATC code	G03FA01 (WHO) ;
Legal status
Legal status	US: ℞-only ;
Identifiers
CAS Number	77728-33-7;

Estradiol/levonorgestrel (E2/LNG), sold under brand name Climara Pro, is a combination of estradiol (E2) and levonorgestrel (LNG) which is used in menopausal hormone therapy.^[1]^[2]^[3] It is a 22-cm² transdermal patch containing 4.4 mg estradiol and 1.39 mg levonorgestrel and delivers 45 μg/day estradiol and 15 μg/day levonorgestrel.^[1]^[4] E2/LNG was approved for medical use in the United States in 2003.^[5]

References[]

^ ^a ^b "Climara Pro Prescribing Information" (PDF). U.S. Food and Drug Administration.
^ Shulman LP (December 2004). "17Beta-estradiol/levonorgestrel transdermal system for the management of the symptomatic menopausal woman". Expert Opinion on Pharmacotherapy. 5 (12): 2559–66. doi:10.1517/14656566.5.12.2559. PMID 15571472. S2CID 24659973.
^ Dando TM, Perry CM (2004). "17 beta-estradiol/levonorgestrel transdermal system". Treatments in Endocrinology. 3 (5): 319–24. doi:10.2165/00024677-200403050-00005. PMID 15330679. S2CID 72554239.
^ Wiedersberg S, Guy RH (September 2014). "Transdermal drug delivery: 30+ years of war and still fighting!" (PDF). Journal of Controlled Release. 190: 150–6. doi:10.1016/j.jconrel.2014.05.022. PMID 24852092.
^ Traynor K (February 2004). "New drug and biological product approvals, 2003". American Journal of Health-System Pharmacy. 61 (4): 338–340. doi:10.1093/ajhp/61.4.338. PMID 15011760.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by .

[Climara_Pro-Label-1] "Climara Pro Prescribing Information" (PDF). U.S. Food and Drug Administration.

[pmid15571472-2] Shulman LP (December 2004). "17Beta-estradiol/levonorgestrel transdermal system for the management of the symptomatic menopausal woman". Expert Opinion on Pharmacotherapy. 5 (12): 2559–66. doi:10.1517/14656566.5.12.2559. PMID 15571472. S2CID 24659973.

[pmid15330679-3] Dando TM, Perry CM (2004). "17 beta-estradiol/levonorgestrel transdermal system". Treatments in Endocrinology. 3 (5): 319–24. doi:10.2165/00024677-200403050-00005. PMID 15330679. S2CID 72554239.

[pmid24852092-4] Wiedersberg S, Guy RH (September 2014). "Transdermal drug delivery: 30+ years of war and still fighting!" (PDF). Journal of Controlled Release. 190: 150–6. doi:10.1016/j.jconrel.2014.05.022. PMID 24852092.

[pmid15011760-5] Traynor K (February 2004). "New drug and biological product approvals, 2003". American Journal of Health-System Pharmacy. 61 (4): 338–340. doi:10.1093/ajhp/61.4.338. PMID 15011760.

[1]

[2]

[3]

[4]

[5]

Estradiol/levonorgestrel

See also[]

References[]